Intech biopharm
NettetINTECH BIOPHARM CORPORATION : Forcasts, revenue, earnings, analysts expectations, ratios for INTECH BIOPHARM CORPORATION Stock 6461 … Nettet31. des. 2024 · Die Intech Biopharm Corporation hat die Ergebnisse für das Geschäftsjahr zum 31. Dezember 2024 bekannt gegeben. Für das Gesamtjahr meldete das Unternehmen einen Umsatz von TWD 23,65 Millionen im... 6 April 2024
Intech biopharm
Did you know?
NettetIntech Biopharm is a pharmaceutical company that develops, produces and markets specialized drugs focused on respiratory treatment. Lists Featuring This Company. Edit Lists Featuring This Company Section. Biopharma Companies With … Nettet益得生技成立於2010年，專精於研發治療氣喘等肺部疾病之學名藥及新藥，並積極發展抗癌等領域之新藥研發，擁有全球少數、國內唯一的HFA MDI（氫氟烷定量噴霧吸入劑）技 …
http://www.intechbiopharm.com/en/ http://www.synmosa.com.hk/EN/
NettetIntech Biopharm. Ltd 益得生技 175 followers on LinkedIn. We are a pharmaceutical company that develops, produces and markets specialized drugs focusing on the … NettetINTECH BIOPHARM LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of inhalants and related products. The Company's main products include respiratory drugs, the Duasma hexafluoroacetone (HFA) metered-dose inhalers (MDIs) and the Synvent HFA MDIs.
NettetIntech Biopharm (TPEX:6461) earnings and revenue forecasts, price targets, future return on equity. Compare Intech Biopharm Corporation's growth forecast against it's industry peers. Home Markets Discover Watchlist Portfolios Screener. Intech Biopharm Corporation. TPEX:6461 Stock Report. Mkt Cap: NT$4.2b.
NettetHFA MDI Technology. Product development and analysis of Synmosa's unique technological platform of HFA MDI (Metered Dose Inhaler) complies with the latest international regulatory requirements. dr. todd ratliff dentistryNettetIntech Biopharm currently focuses mainly on developing drugs for obstructive airway diseases such as bronchial asthma and chronic obstructive pulmonary disease (COPD). By owning the superior HFA MDI platforms with facilities at the high level as EMA and US FDA standard, we have received a number of governmental grants and awards, and … columbus day in massachusettsNettet9. des. 2024 · Brief Summary: The primary objective of this study is to compare the efficacy and safety of budesonide HFA MDI 200 mcg 2 puffs BID versus budesonide … columbus day in americaNettet31. des. 2024 · Die Intech Biopharm Corporation hat die Ergebnisse für das Geschäftsjahr zum 31. Dezember 2024 bekannt gegeben. Für das Gesamtjahr meldete … columbus day in floridaNettetINTECH BIOPHARM CORPORATION (TWO:6461) : Stock quote, stock chart, quotes, analysis, advice, financials and news for share INTECH BIOPHARM CORPORATION Taipei Exchange: 6461 Taipei Exchange dr todd reaginNettetIntech Biopharm. Ltd 益得生技 is a Pharmaceuticals, Drug Manufacturing & Research, and Drug Discovery company located in Taipei, TW with $5.00 Million in revenue and 23 employees. Find top employees, contact details and business statistics at RocketReach. dr todd reynolds midlothianNettetSynmosa Biopharma Inks NT$210 million Licensing Agreement for Budesonide. 2016.05.09. Synmosa's Posts Highest Single-Quarter Earnings Ever, EPS Hits NT$1.35. 2016.05.03. Synmosa Signs NT$420 million Deal with Hemony Pharma. 2016.03.24. Synmosa Collaborates with InnoPharmax to Branch Out into Production of API. dr todd richards az